Akari Therapeutics

IPO

Public · London, United Kingdom · Founded 2012 · $14.6M raised

Headquarters
London
Employees
1–10
Founded
2012
Business Model
B2B
Total Funding
$14.6M
Last Round
$5.0M Venture RoundDec 2025
Rounds
3
Type
Public

About

Akari Therapeutics is a clinical-stage oncology biotechnology company developing next-generation antibody-drug conjugates (ADCs) with a novel spliceosome-targeting payload (PH1). The company's lead program, AKTX-101, is advancing toward a Phase 1 first-in-human clinical trial. Akari is listed on Nasdaq (AKTX) and operates from New York and Boston.

Summary

Akari Therapeutics is an Antibody-Drug Conjugates company based in London, United Kingdom, founded in 2012. It has raised $14.6M in total across 3 rounds, most recently a $5.0M Venture Round round in Dec 2025.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Venture RoundVenture RoundDec 2025
$5.0M

Sign up to see all 3 rounds

Venture Round — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Akari Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/akari-therapeutics"><img src="https://indexed.vc/api/badge/company/akari-therapeutics" alt="Akari Therapeutics on Indexed.vc" width="260" height="76" /></a>